Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
PACTR202004893013257Phase 3Not yet recruiting
- Sponsor
- Dr Birgit Whitman
- Start
- Apr 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine, lopinavir and ritonavir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Dr Birgit Whitman. Primary endpoints: Composite pulmonary complication outcome, Pneumonia and 2 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
hydroxychloroquinelopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202004893013257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202004893013257.